Every month, a vast number of papers are important publications, each issue of Climacteric published in medical journals around the world.will contain a selection of abstracts from recently Although only a few are likely to be of specific published papers, which are judged by the Editors interest, many papers will contain useful informa-to be of the greatest general interest to those tion. To help you keep up-to-date with the more involved in this important area of research. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study S. M . Gapstur, M . Morrow and T. A. Sellers J Am Med Assoc 1999;281:2091-7 Context Long-term, postmenopausal use of hormone replacement therapy (HRT) appears to increase breast cancer risk. Whether the effect of H R T use o n risk of breast cancer varies among histological types of invasive carcinoma is unknown. Objective To determine associations between H R T use and risk of ductal carcinoma in situ (DCIS), invasive carcinoma with favorable histology, and invasive ductal or lobular carcinoma. Design Prospective cohort study whose participants were followed up continuously for 11 years from January 1986 to December 1996. Setting and participants Iowa Women's Health Study, a population-based random sample of postmenopausal women aged 55 to 69 years in 1986. A total of 1520 incident breast cancer cases occurred in the at-risk cohort of 37 105 women. Main outcome measures Multivariate-adjusted relative risk (RR) of tumor-specific breast cancers associated with duration of ever, current, or past H R T use. Results Duration of ever HRT use was associated with risk of invasive carcinoma with a favorable histology, with an RR of 1.81 (%0/, confidence interval [CI], 1.07-3.07) for those who used HRT 5 or fewer years vs an RR of 2.65 (95% CI, 1.34-5.23) for those who used H R T for more than 5 years ( p for trend = 0.005) after adjustment for age and other breast cancer risk factors. There was no association between ever HRT use and the incidence of DCIS or invasive ductal or lobular carcinoma. Among current hormone users, after adjusting for age and other breast cancer risk factors, the RRs (95 YO CIS) of invasive carcinoma with a favorable histology were 4.42 (2.00-9.76) and 2.63 ( 1.18-5.89) for 5 or fewer years of use and more than 5 years of use, respectively. Risk of invasive ductal or lobular carcinoma was associated with current use (< or = 5 years) of H R T with an RR of 1.38 (95% CI, 1.03-1.85). Conclusions Exposure to HRT was associated most strongly with a n increased risk of invasive breast cancer with a favorable prognosis. These data add important clinical information for assessing the risks and benefits of HRT use.
Osteoporos Int 1999;9:158-62There is controversy about the ideal timing of continuously were selected from 365 postmenohormone replacement therapy (HRT) and durapausal monozygotic ( M Z ) and dizygotic (DZ) tion of treatment. In this study we have examined pairs recruited as part of the St. Thomas' Adu...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.